{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005140","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.986942+00:00","generated_at":"2026-06-18T22:15:47.155907+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kezar Life Sciences President & CSO Christopher Kirk resigns; internal promotions announced","bullets":["Christopher Kirk, Ph.D. resigns as President and CSO effective April 21, 2023 for personal reasons; will remain on Board as strategic advisor.","Neel Anand, DPhil promoted to SVP, Research and Drug Discovery; Kieron Wesson, Ph.D. promoted to SVP, CMC and Supply Chain.","Both new SVPs report to CEO John Fowler as part of the company's succession plan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005140","json":"https://secwatch.observer/filing/0000950170-23-005140.json","markdown":"https://secwatch.observer/filing/0000950170-23-005140.md","text":"https://secwatch.observer/filing/0000950170-23-005140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023005140/0000950170-23-005140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023005140/kzr-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:15:47.155907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a002176bcb","claim":"Christopher Kirk resigned as President and Chief Scientific Officer at Kezar Life Sciences, Inc..","evidence_excerpt":"On February 27, 2023, Christopher Kirk, Ph.D., President, Chief Scientific Officer and member of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”), provided notice of his intention to resign from the positions of President and Chief Scientific Officer of the Company for personal reasons, effective April 21, 2023 (the “Resignation Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023005140/0000950170-23-005140-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}